COVID-19 illness in native and immunosuppressed states: A clinical-therapeutic staging proposal

doi:10.1016/j.healun.2020.03.012

Editorial

. 2020 May;39(5):405-407.

doi: 10.1016/j.healun.2020.03.012. Epub 2020 Mar 20.

COVID-19 illness in native and immunosuppressed states: A clinical-therapeutic staging proposal

Hasan K Siddiqi¹, Mandeep R Mehra²

Affiliations

¹ Department of Internal Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
² Department of Internal Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts. Electronic address: mmehra@bwh.harvard.edu.

PMID: 32362390
PMCID: PMC7118652
DOI: 10.1016/j.healun.2020.03.012

Editorial

COVID-19 illness in native and immunosuppressed states: A clinical-therapeutic staging proposal

Hasan K Siddiqi et al. J Heart Lung Transplant. 2020 May.

. 2020 May;39(5):405-407.

doi: 10.1016/j.healun.2020.03.012. Epub 2020 Mar 20.

Authors

Hasan K Siddiqi¹, Mandeep R Mehra²

Affiliations

¹ Department of Internal Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
² Department of Internal Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts. Electronic address: mmehra@bwh.harvard.edu.

PMID: 32362390
PMCID: PMC7118652
DOI: 10.1016/j.healun.2020.03.012

No abstract available

PubMed Disclaimer

Figures

**Figure 1**
Classification of COVID-19 disease states and potential therapeutic targets. The figure illustrates 3 escalating phases of COVID-19 disease progression, with associated signs, symptoms, and potential phase-specific therapies. ARDS, acute respiratory distress syndrome; CRP, C-reactive protein; JAK, janus kinase; LDH, lactate dehydrogenase; NT-proBNP, N-terminal pro B-type natriuretic peptide; SIRS, systemic inflammatory response syndrome; GM-CSF, Granulocyte Macrophage Colony Stimulating Factor.

See this image and copyright information in PMC

Comment in

COVID-19: Timing is Important.
de Simone G, Mancusi C. de Simone G, et al. Eur J Intern Med. 2020 Jul;77:134-135. doi: 10.1016/j.ejim.2020.04.019. Epub 2020 Apr 13. Eur J Intern Med. 2020. PMID: 32362362 Free PMC article. No abstract available.

Comment on

Epidemiologic and clinical characteristics of heart transplant recipients during the 2019 coronavirus outbreak in Wuhan, China: A descriptive survey report.
Ren ZL, Hu R, Wang ZW, Zhang M, Ruan YL, Wu ZY, Wu HB, Hu XP, Hu ZP, Ren W, Li LC, Dai FF, Liu H, Cai X. Ren ZL, et al. J Heart Lung Transplant. 2020 May;39(5):412-417. doi: 10.1016/j.healun.2020.03.008. Epub 2020 Mar 25. J Heart Lung Transplant. 2020. PMID: 32362392 Free PMC article.

Cited by

Triage tool for suspected COVID-19 patients in the emergency room: AIFELL score.
Levenfus I, Ullmann E, Battegay E, Schuurmans MM. Levenfus I, et al. Braz J Infect Dis. 2020 Sep-Oct;24(5):458-461. doi: 10.1016/j.bjid.2020.07.003. Epub 2020 Aug 20. Braz J Infect Dis. 2020. PMID: 32828735 Free PMC article.
COVID-19: NAD⁺ deficiency may predispose the aged, obese and type2 diabetics to mortality through its effect on SIRT1 activity.
Miller R, Wentzel AR, Richards GA. Miller R, et al. Med Hypotheses. 2020 Nov;144:110044. doi: 10.1016/j.mehy.2020.110044. Epub 2020 Jun 29. Med Hypotheses. 2020. PMID: 32758884 Free PMC article.
Therapeutic use of calpeptin in COVID-19 infection.
Inal J, Paizuldaeva A, Terziu E. Inal J, et al. Clin Sci (Lond). 2022 Oct 28;136(20):1439-1447. doi: 10.1042/CS20220638. Clin Sci (Lond). 2022. PMID: 36268783 Free PMC article.
Targeting complement in severe coronavirus disease 2019 to address microthrombosis.
Valga F, Vega-Díaz N, Macia M, Monzón T, Rodriguez-Perez JC. Valga F, et al. Clin Kidney J. 2020 Jun 12;13(3):477-479. doi: 10.1093/ckj/sfaa095. eCollection 2020 Jun. Clin Kidney J. 2020. PMID: 32695331 Free PMC article. No abstract available.
The use of Janus Kinase inhibitors in hospitalized patients with COVID-19: Systematic review and meta-analysis.
Wijaya I, Andhika R, Huang I, Purwiga A, Budiman KY, Bashari MH, Reniarti L, Roesli RMA. Wijaya I, et al. Clin Epidemiol Glob Health. 2021 Jul-Sep;11:100755. doi: 10.1016/j.cegh.2021.100755. Epub 2021 May 2. Clin Epidemiol Glob Health. 2021. PMID: 33969237 Free PMC article.

See all "Cited by" articles

References

1. Novel coronavirus pneumonia emergency response epidemiology team The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China [in Chinese] Zhonghua Liu Xing Bing Xue Za Zhi. 2020;41:145–151. - PubMed
1. Wang M, Cao R, Zhang L. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30:269–271. - PMC - PubMed
1. Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19 [e-pub ahead of print]. N Engl J Med doi: 10.1056/NEJMoa2001282, Accessed March 15, 2020. - PMC - PubMed
1. Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet. 2020;395:473–475. - PMC - PubMed
1. Li F, Cai J, Dong N. First cases of COVID-19 in heart transplantation From China. J Heart Lung Transplant. 2020;39:418–419. - PMC - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- The Lens - Patent Citations Database
Medical
- MedlinePlus Health Information

[1] Novel coronavirus pneumonia emergency response epidemiology team The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China [in Chinese] Zhonghua Liu Xing Bing Xue Za Zhi. 2020;41:145–151. - PubMed

[2] Novel coronavirus pneumonia emergency response epidemiology team The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China [in Chinese] Zhonghua Liu Xing Bing Xue Za Zhi. 2020;41:145–151. - PubMed

[3] Wang M, Cao R, Zhang L. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30:269–271. - PMC - PubMed

[4] Wang M, Cao R, Zhang L. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30:269–271. - PMC - PubMed

[5] Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19 [e-pub ahead of print]. N Engl J Med doi: 10.1056/NEJMoa2001282, Accessed March 15, 2020. - PMC - PubMed

[6] Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19 [e-pub ahead of print]. N Engl J Med doi: 10.1056/NEJMoa2001282, Accessed March 15, 2020. - PMC - PubMed

[7] Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet. 2020;395:473–475. - PMC - PubMed

[8] Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet. 2020;395:473–475. - PMC - PubMed

[9] Li F, Cai J, Dong N. First cases of COVID-19 in heart transplantation From China. J Heart Lung Transplant. 2020;39:418–419. - PMC - PubMed

[10] Li F, Cai J, Dong N. First cases of COVID-19 in heart transplantation From China. J Heart Lung Transplant. 2020;39:418–419. - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

COVID-19 illness in native and immunosuppressed states: A clinical-therapeutic staging proposal

Affiliations

COVID-19 illness in native and immunosuppressed states: A clinical-therapeutic staging proposal

Authors

Affiliations

Figures

Comment in

Comment on

Similar articles

Cited by

References

Publication types

MeSH terms

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical